Immunohistological expression of SOX-10 in triple-negative breast cancer

• Verfasst von: Kriegsmann, Katharina [VerfasserIn]
• Verfasst von: Flechtenmacher, Christa [VerfasserIn]
• Verfasst von: Heil, Jörg [VerfasserIn]
• Verfasst von: Mechtersheimer, Gunhild [VerfasserIn]
• Verfasst von: Sinn, Peter [VerfasserIn]
• Verfasst von: Kriegsmann, Mark [VerfasserIn]
• Titel: Immunohistological expression of SOX-10 in triple-negative breast cancer
• Titelzusatz: a descriptive analysis of 113 samples
• Verf.angabe: Katharina Kriegsmann, Christa Flechtenmacher, Jörg Heil, Jörg Kriegsmann, Gunhild Mechtersheimer, Sebastian Aulmann, Wilko Weichert, Hans-Peter Sinn and Mark Kriegsmann
• E-Jahr: 2020
• Jahr: 3 September 2020
• Umfang: 17 S.
• Fussnoten: Gesehen am 04.12.2020
• Titel Quelle: Enthalten in: International journal of molecular sciences
• Ort Quelle: Basel : Molecular Diversity Preservation International, 2000
• Jahr Quelle: 2020
• Band/Heft Quelle: 21(2020,17) Artikel-Nummer 6407, 17 Seiten
• ISSN Quelle: 1422-0067
• ISSN Quelle: 1661-6596
• DOI: doi:10.3390/ijms21176407
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: immunohistochemistry
• Sach-SW: SOX10
• Sach-SW: triple-negative breast cancer
• K10plus-PPN: 1742108415

Abstract

Background: SRY-related HMG-box 10 (SOX-10) is commonly expressed in triple negative breast cancer (TNBC). However, data on the biological significance of SOX-10 expression is limited. Therefore, we investigated immunhistological SOX-10 expression in TNBC and correlated the results with genetic alterations and clinical data. Methods: A tissue microarray including 113 TNBC cases was stained by SOX-10. Immunohistological data of AR, BCL2, CD117, p53 and Vimentin was available from a previous study. Semiconductor-based panel sequencing data including commonly altered breast cancer genes was also available from a previous investigation. SOX-10 expression was correlated with clinicopathological, immunohistochemical and genetic data. Results: SOX-10 was significantly associated with CD117 and Vimentin, but not with AR expression. An association of SOX-10 with BCL2, EGFR or p53 staining was not observed. SOX-10-positive tumors harbored more often TP53 mutations but less frequent mutations of PIK3CA or alterations of the PIK3K pathway. SOX-10 expression had no prognostic impact either on disease-free, distant disease-free, or overall survival. Conclusions: While there might be a value of SOX-10 as a differential diagnostic marker to identify metastases of TNBC, its biological role remains to be investigated.